In a report released today, Joel Beatty from Robert W. Baird maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $131.00. The company’s shares opened today at $127.85.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Beatty is a 5-star analyst with an average return of 12.6% and a 48.98% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Neurogene, Argenx Se, and ACADIA Pharmaceuticals.
In addition to Robert W. Baird, Blueprint Medicines also received a Buy from Wells Fargo’s Derek Archila in a report issued yesterday. However, today, Barclays maintained a Hold rating on Blueprint Medicines (NASDAQ: BPMC).
Based on Blueprint Medicines’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $149.41 million and a net profit of $496 thousand. In comparison, last year the company earned a revenue of $96.12 million and had a net profit of $89.14 million
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Read More on BPMC:
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
- Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens
- Blueprint downgraded to Market Perform from Outperform at Citizens JMP
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research